CIC
VYGR icon

Chase Investment Counsel’s Voyager Therapeutics VYGR Stock Holding History

Chase Investment Counsel’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,800
Closed -$76K – 170
2026
Q1 		$76K Buy
+19,800
New +$78K 0.02% 149

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Chase Investment Counsel's VYGR Position: Q2 2026 in Review

Chase Investment Counsel sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 19,800 shares — an estimated $76K sold.

Chase Investment Counsel first reported a position in VYGR in Q1 2026 and held it in 1 quarter. The position peaked at $76K in Q1 2026. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Chase Investment Counsel reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Chase Investment Counsel sold 19,800 Voyager Therapeutics shares in Q2 2026, an estimated $76K.
  • Chase Investment Counsel first reported a position in Voyager Therapeutics in Q1 2026 and held it in 1 quarter.
  • Chase Investment Counsel's Voyager Therapeutics position peaked at $76K in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.